山东步长制药股份有限公司 2025年第一次临时股东会决议公告

Group 1 - The company held its first extraordinary general meeting of shareholders on November 17, 2025, with no resolutions being rejected [2] - The meeting was legally convened and conducted, with the presence of all directors and supervisors, and was chaired by the board secretary [3][4] - Several resolutions were passed, including the cancellation of the supervisory board and adjustments to the number of directors [4][5][6] Group 2 - The company announced the election of Wu Bing as the employee representative director of the fifth board of directors, effective immediately [9][10] - Wu Bing has been with the company since 2000 and currently serves as the director of the securities department [11] Group 3 - The company plans to invest in a new joint venture, Nanjing Keyinno Biotechnology Co., Ltd., with a registered capital of 2 million yuan, where the company’s subsidiary will hold an 11.11% stake [12][14] - The investment will not change the scope of the company's consolidated financial statements and does not require shareholder approval [14][18] - The joint venture aims to enhance business development and leverage the strengths of all parties involved [28]